2003 - Fellow of the Royal Society of Edinburgh
His scientific interests lie mostly in Internal medicine, Endocrinology, Cholesterol, Myocardial infarction and Pravastatin. The various areas that Chris J. Packard examines in his Internal medicine study include Surgery and Cardiology. His studies deal with areas such as Framingham Risk Score and Case-control study as well as Cardiology.
His study focuses on the intersection of Cholesterol and fields such as Blood plasma with connections in the field of Differential centrifugation, Ultracentrifuge, Arteriosclerosis, Preeclampsia and Gestational age. His study in Myocardial infarction is interdisciplinary in nature, drawing from both Stroke, Vascular disease, Bioinformatics and Hazard ratio. His Pravastatin study combines topics from a wide range of disciplines, such as Randomized controlled trial, Heart Protection Study and Gerontology.
Chris J. Packard focuses on Internal medicine, Endocrinology, Cholesterol, Lipoprotein and Apolipoprotein B. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Cardiology. His research in Cardiology focuses on subjects like Risk factor, which are connected to Vascular disease and Diabetes mellitus.
The study incorporates disciplines such as Lipoprotein lipase and Lipolysis in addition to Apolipoprotein B. His studies in Pravastatin integrate themes in fields like Prospective cohort study, Surgery, Stroke, Myocardial infarction and Hazard ratio. His research investigates the connection between Myocardial infarction and topics such as Statin that intersect with problems in Clinical trial.
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Cholesterol, Apolipoprotein B and Triglyceride. His research related to Myocardial infarction, Statin, Lipoprotein, Disease and Randomized controlled trial might be considered part of Internal medicine. His Myocardial infarction study also includes fields such as
His Cholesterol study combines topics in areas such as Coronary heart disease and Odds ratio. His work deals with themes such as Chylomicron, Hypertriglyceridemia and Apolipoprotein C-III, which intersect with Apolipoprotein B. His Triglyceride study integrates concerns from other disciplines, such as Triglyceride transport and Metabolism.
Internal medicine, Myocardial infarction, Randomized controlled trial, Bioinformatics and Cholesterol are his primary areas of study. The Internal medicine study combines topics in areas such as Endocrinology and Surgery. His research integrates issues of Fructose and Heterozygote advantage in his study of Endocrinology.
His Myocardial infarction research integrates issues from Stroke, Lower risk and Pravastatin. His research in Randomized controlled trial intersects with topics in Relative risk, Prospective cohort study, Mendelian Randomization Analysis and Disease. His Cholesterol research is multidisciplinary, incorporating perspectives in Receptor, Knockout mouse and Acute-phase protein.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J Shepherd;S M Cobbe;I Ford;C G Isles.
The New England Journal of Medicine (1995)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
James Shepherd;Gerard J Blauw;Michael B Murphy;Edward Lem Bollen.
The Lancet (2002)
Major lipids, apolipoproteins, and risk of vascular disease
E Di Angelantonio;N Sarwar;P Perry.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar;David Preiss;Heather M Murray;Paul Welsh.
The Lancet (2010)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A Ference;Henry N Ginsberg;Ian T. Graham;Kausik K Ray.
European Heart Journal (2017)
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
Naveed Sattar;Allan Gaw;Olga Scherbakova;Ian Ford.
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials
J Shepherd;SM Cobbe;AR Lorimer;JH McKillop.
The Lancet (1996)
Pravastatin and the Development of Diabetes Mellitus Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
Dilys J. Freeman;John Norrie;Naveed Sattar;R. Dermot G. Neely.
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)
A M Wallace;A D McMahon;C J Packard;A Kelly.
C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
Stephen Kaptoge;Emanuele Di Angelantonio;Lisa Pennells;Angela M. Wood.
The New England Journal of Medicine (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: